Cell BioEngines Secures an Additional $2 Million in Funding From SOSV and the Empire State Development’s New York Ventures
July 20, 2024 16:11 ET
|
Cell BioEngines, Inc.
NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a New York, USA-based company researching stem cells in order to develop new cell therapies unlocked $1.75 million additional funds...
Cell BioEngines to Present at the 2024 BIO CEO & Investor Conference
February 08, 2024 11:45 ET
|
Cell BioEngines, Inc.
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a biotechnology company focused on the development of ‘off-the-shelf’ ‘non-gene modified’ hematopoietic stem cells and its derived...
SOSV-backed Biotech Firm Cell BioEngines Decides New York Is the Place to Be
January 13, 2024 14:11 ET
|
Cell BioEngines, Inc.
Cell BioEngines, Inc., founded by visionary Dr. Ajay Vishwakarma aiming to turn cancer into a curable disease announced today that the SOSV-backed company
Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program
December 29, 2023 18:13 ET
|
Cell BioEngines, Inc.
NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood...
Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology
September 07, 2023 11:16 ET
|
Cell BioEngines, Inc.
BOSTON and NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc. is strengthening its Intellectual Property portfolio with a patent licensed from the Icahn School of Medicine at Mount...
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
January 25, 2023 21:15 ET
|
Cell BioEngines, Inc.
BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors,...